Sanofi: 2019 adjusted EPS up 6.8%
(CercleFinance.com) - Sanofi has published 2019 business EPS of 5.
99 euros, up 6.8% at constant exchange rates (CER), with a corresponding operating margin that is up 1.2 point at 27%, thus approaching its target of 30% for 2022.
Net sales were 36.13 billion euros, up 4.8% as reported, and up 2.8% at CER (up 3.6% at CER and consolidation scope), including vaccine sales of 5.73 billion euros, up 9.3% and therefore in line with the average growth rate expected between 2018 and 2025.
Sanofi's board of directors has proposed a dividend of 3.15 euros, representing the 26th consecutive annual increase. The group expects its business EPS will be around 5% at CER, excluding any major unforeseen events.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
99 euros, up 6.8% at constant exchange rates (CER), with a corresponding operating margin that is up 1.2 point at 27%, thus approaching its target of 30% for 2022.
Net sales were 36.13 billion euros, up 4.8% as reported, and up 2.8% at CER (up 3.6% at CER and consolidation scope), including vaccine sales of 5.73 billion euros, up 9.3% and therefore in line with the average growth rate expected between 2018 and 2025.
Sanofi's board of directors has proposed a dividend of 3.15 euros, representing the 26th consecutive annual increase. The group expects its business EPS will be around 5% at CER, excluding any major unforeseen events.
Copyright (c) 2020 CercleFinance.com. All rights reserved.